| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Crizotinib | PF-1066; PF-2341066; PF-02341066; PF-002341066 | Approved | Pfizer Inc | 赛可瑞, Xalkori | United States | Carcinoma, Non-Small-Cell Lung | Pf Prism Cv | 2011-08-26 | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Granuloma, Plasma Cell; Hematologic Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Multiple Myeloma; Myofibroma; Neoplasm Metastasis; Neoplasms; Neurilemmoma; Neuroblastoma; Neurofibromatosis 2; Renal Insufficiency; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uveal melanoma | Details |